MACK Merrimack Pharmaceuticals, Inc.

3.02
0  -1%
Previous Close 3.06
Open 3.07
Price To book 0.00
Market Cap 394.32M
Shares 130,570,000
Volume 1,257,360
Short Ratio 17.32
Av. Daily Volume 3,432,020

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2018.
MM-141
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
MM-302 HERMIONE
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
ONIVYDE
Cancer - second line pancreatic
Phase 2 initiated mid Feb 2015. Data due by end of 2018.
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
ONIVYDE
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
ONIVYDE
Cancer - front line pancreatic

Latest News

  1. Merrimack (MACK) Starts Enrollment in Solid Tumors Study
  2. ​Merrimack asset sale prompts legal blowback
  3. Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors
  4. Lawyer: former Merrimack employee accused of insider trading to fight charges
  5. Merrimack Pharmaceuticals, Inc. :MACK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
  6. Merrimack Pharmaceuticals, Inc. :MACK-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  7. Biotech's Fall as President Trump to Address Pricing Concerns: Today's Research Reports on Arena Pharmaceuticals and Merrimack Pharmaceuticals
  8. MERRIMACK PHARMACEUTICALS INC Financials
  9. Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top
  10. These 5 Stocks Under $10 Could Explode Up Soon
  11. Edited Transcript of MACK earnings conference call or presentation 1-Mar-17 1:30pm GMT
  12. MERRIMACK PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
  13. Merrimack's (MACK) Q4 Loss In-Line With Estimates
  14. Merrimack reports 4Q loss
  15. Merrimack reports 4Q loss
  16. Q4 2016 Merrimack Pharmaceuticals Inc Earnings Release - Before Market Open
  17. Merrimack Reports Fourth Quarter and Full-Year 2016 Financial Results
  18. Merrimack Announces Timing of Fourth Quarter 2016 Investor Conference Call
  19. Merrimack (MACK): What Awaits the Stock in Q4 Earnings?
  20. Is Merrimack Pharmaceuticals Worth Stashing in Portfolios?